Clinical Trial Update: Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment [Phase 1]

View source ↗

Summary

Phase 1 extension study of ALN-VSP02 in cancer patients who responded to ALN-VSP02 treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ALN-VSP02

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED